PPARgamma-mediated insulin sensitization: the importance of fat versus muscle.
about
Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's diseasePeroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a reviewOphiocordyceps formosana improves hyperglycemia and depression-like behavior in an STZ-induced diabetic mouse modelEffects of interventions on adiponectin and adiponectin receptors.Nr4a1 is required for fasting-induced down-regulation of Pparγ2 in white adipose tissue.Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic DrugsMolecular mechanism of insulin resistance in obesity and type 2 diabetes.Involvement of inducible 6-phosphofructo-2-kinase in the anti-diabetic effect of peroxisome proliferator-activated receptor gamma activation in mice.CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models.Immunoreactivities of PPARγ2, leptin and leptin receptor in oviduct of Chinese brown frog during breeding period and pre-hibernation.Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective.PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.Pathogenesis of alcoholic liver disease: role of oxidative metabolism.Keap1-knockdown decreases fasting-induced fatty liver via altered lipid metabolism and decreased fatty acid mobilization from adipose tissueNitroalkene fatty acids mediate activation of Nrf2/ARE-dependent and PPARγ-dependent transcription by distinct signaling pathways and with significantly different potencies.Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.Regulation of SREBPs by Sphingomyelin in Adipocytes via a Caveolin and Ras-ERK-MAPK-CREB Signaling PathwayApplication of back propagation artificial neural network on genetic variants in adiponectin ADIPOQ, peroxisome proliferator-activated receptor-γ, and retinoid X receptor-α genes and type 2 diabetes risk in a Chinese Han populationThe role of insulin resistance in the development of muscle wasting during cancer cachexia.Hypoglycemic Activity through a Novel Combination of Fruiting Body and Mycelia of Cordyceps militaris in High-Fat Diet-Induced Type 2 Diabetes Mellitus Mice.Enhanced Nrf2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice.Peroxisome proliferator-activated receptor-γ activation enhances insulin-stimulated glucose disposal by reducing ped/pea-15 gene expression in skeletal muscle cells: evidence for involvement of activator protein-1The potential of antidiabetic thiazolidinediones for anticancer therapy.Metabolic reprogramming in dietary restriction.UV-induced inhibition of adipokine production in subcutaneous fat aggravates dermal matrix degradation in human skin.AMPK, insulin resistance, and the metabolic syndrome.Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production.Heat shock factor-1 knockout enhances cholesterol 7α-hydroxylase (CYP7A1) and multidrug transporter (MDR1) gene expressions to attenuate atherosclerosis.Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathwaysComparative Effect of Insulin Sensitizers and Statin on Metabolic Profile and Ultrasonographical Score in Non Alcoholic Fatty Liver Disease.Down-regulation of lipoprotein lipase increases glucose uptake in L6 muscle cells.Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions.n-3 PUFA: bioavailability and modulation of adipose tissue function.Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.Father's obesity programs the adipose tissue in the offspring via the local renin-angiotensin system and MAPKs pathways, especially in adult male mice.Peroxisome proliferator-activated receptor α (PPARα) contributes to control of melanogenesis in B16 F10 melanoma cells.The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.
P2860
Q26866392-676131BF-409B-4379-876E-32A92E4ED097Q26866784-B63023D0-C66D-494E-B276-D47CDAAE580EQ28829254-B51AED50-A2B1-4381-9062-82991169C2A6Q33629849-6FCE0CC3-A8B5-4AF2-BB16-90C22C2110AEQ33636236-B2DF3440-8E74-48F5-B2DA-544BC6F0E3A5Q33809886-80F59D35-A29C-43BB-9C38-EA14CE3FAF8DQ33893897-E769C32D-3126-4CFF-8641-C7BE5274764EQ34025180-0DC235D0-DB55-41E9-B4F7-438F04D92979Q34067485-4BAA3444-D2ED-4282-A985-77CC77A8A29EQ34325863-71B50FD3-7475-4D52-9C08-8DCB27561742Q34412650-C910ED0A-ACB5-4F66-BEA8-5C56CF99129AQ34689526-4F850F76-F9B5-4AC9-AB16-75E775BC9E4FQ34750539-31B0365D-4796-4E3D-B88A-5893129950CDQ35041508-4B2B51AB-5413-40EB-8429-22D0E3C10CDAQ35201387-73DE0842-5E82-4F11-BD8D-F1C38BAF7C48Q35636191-0C3F1E6B-95DE-435C-A4CF-E9B28896D225Q35731006-2451330C-9C81-4993-BF37-756E9AC26C6FQ35772627-DED66668-9B9D-4DFD-A924-87F259E803CBQ35828084-67ED1D29-4DD9-4792-8AA1-C604C669B1EEQ35901526-14079422-A0C2-4735-826F-E62A88372889Q36410781-9BAE04CD-597E-4AB3-AB4F-4CEE78D33DC6Q36466778-F35AD144-D993-400A-B8B2-B66582D21EFFQ36568732-44900ED3-A437-416C-BC3E-D81427DA9748Q36633913-D79028C4-83B6-4CF5-BBC4-12332135793EQ36886143-5A962F00-B36C-400D-A510-7307697F87B6Q36966839-FA01BD78-1492-405B-9731-82FB9295EDC3Q36976999-155A4F3B-7D7A-4855-B4D1-200870FFA0EEQ37007991-B2F6AEF1-89F9-4F95-84A8-CA5A68A72A4EQ37033675-0800A36C-04BA-4CAB-8984-9E3FB04BF196Q37266575-85F44B19-F703-4599-ADC2-E5C81C4D5FEFQ37359756-8DA1B14C-AA3F-4F96-BA0D-569A2C67A81EQ37375539-48DBA041-2E6E-42CB-9077-9A10036AC8DEQ37578702-760F36DA-305B-47F4-858C-B4F9931DF983Q37583969-FA566F1B-3CF6-4CAD-83B7-C63F857B70A3Q38290238-BEB73905-698A-44A9-9580-9FBB34579BD7Q38641190-F74DD473-7429-467B-BF2C-ECD07FDDE443Q38674739-6BBF459E-5EFD-4F43-9CF6-D9B24C4862EEQ38680361-2477EF2D-F7A0-44D7-8F76-C23D618A9C89Q38721499-20D257DE-35A0-4D1F-9E5F-DBA602D0D720Q38752520-7A1E22E4-283E-4E9E-92B0-D90034558616
P2860
PPARgamma-mediated insulin sensitization: the importance of fat versus muscle.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
PPARgamma-mediated insulin sensitization: the importance of fat versus muscle.
@ast
PPARgamma-mediated insulin sensitization: the importance of fat versus muscle.
@en
type
label
PPARgamma-mediated insulin sensitization: the importance of fat versus muscle.
@ast
PPARgamma-mediated insulin sensitization: the importance of fat versus muscle.
@en
prefLabel
PPARgamma-mediated insulin sensitization: the importance of fat versus muscle.
@ast
PPARgamma-mediated insulin sensitization: the importance of fat versus muscle.
@en
P2860
P1476
PPARgamma-mediated insulin sensitization: the importance of fat versus muscle.
@en
P2093
Ronald E Law
P2860
P304
P356
10.1152/AJPENDO.00440.2004
P577
2005-02-01T00:00:00Z